A PHASE III, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER - Regional Cancer Care Associates LLC

Clinical Trials

A PHASE III, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Type of Cancer
Breast Oncology
Locations
Hackensack
Sponsor
Roche/Genentech
Protocol Number
WO29522
Cancer Diagnosis
To Learn More Call
201-510-0910